Development and validation of the cognitive stability index, a Web-based protocol for monitoring change in cognitive function

Erlanger, D.; Feldman, D.; Kaplan, D; Theodoracopulos, A

doi:10.1093/arclin/15.8.693a

Search citation statements

Order By: Relevance

Paper Sections

Select...

Results1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2009

2022

Publication Types

Select...

Article5

Book1

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 8 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The battery exhibits good test–retest reliability and minimal practice effects, appearing to be a valid measure of cognitive performance in various populations including non-English–speaking persons. 34 It is argued that the battery is suitable for serial assessment. 33 The CSI subtests and the 4 factors the battery measures display good concurrent validity with standard neuropsychological tests of the same domains.…”

Section: Resultsmentioning

confidence: 99%

Computerized Cognitive Testing for Older Adults

Zygouris

Tsolaki

2014

Am J Alzheimers Dis Other Demen

247

240

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Computerized Cognitive Testing for Older Adults

Zygouris

Tsolaki

2014

Am J Alzheimers Dis Other Demen

247

240

View full text Add to dashboard Cite

show abstract

Neuropsychologic Testing for Chemotherapy-Related Cognitive Impairment

Myers

2010

Chemo Fog

View full text Add to dashboard Cite

Scales as outcome measures for Alzheimer's disease

Black

Greenberg

Ryan

et al. 2009

Alzheimer's & Dementia

View full text Add to dashboard Cite

The assessment of patient outcomes in clinical trials of new therapeutics for Alzheimer's disease (AD) continues to evolve. In addition to assessing drugs for symptomatic relief, an increasing number of trials are focusing on potential disease-modifying agents. Moreover, participants with AD are being studied earlier in their course of disease. As a result, the limitations of current outcome measures have become more apparent, as has the need for better instruments. In recognition of the need to review and possibly revise current assessment measures, the Alzheimer's Association, in cooperation with industry leaders and academic investigators, convened a Research Roundtable meeting devoted to scales as outcome measures for AD clinical trials. The meeting included a discussion of methodological issues in the use of scales in AD clinical trials, including cross-cultural issues. Specific topics related to the use of cognitive, functional, global, and neuropsychiatric scales were also presented. Speakers also addressed academic and industry initiatives for pooling data from untreated and placebo-treated patients in clinical trials. A number of regulatory topics were also discussed with agency representatives. Panel discussions highlighted areas of controversy, in an effort to gain consensus on various topics.

show abstract

Development and validation of the cognitive stability index, a Web-based protocol for monitoring change in cognitive function

Cited by 8 publications

References 0 publications

Computerized Cognitive Testing for Older Adults

Computerized Cognitive Testing for Older Adults

Neuropsychologic Testing for Chemotherapy-Related Cognitive Impairment

Scales as outcome measures for Alzheimer's disease

Contact Info

Product

Resources

About